Clinical Trial

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Study acronym: GLYCO-3P
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-01.
Status change: Not Yet Recruiting → Recruiting 2026-04-14
Trial Details
NCT Number NCT06862739
Lead Sponsor Nabiqasim Industries (Pvt) Ltd
Conditions Diabetes Mellitus, Type 2 DM
Enrollment 800 participants
Start Date 2025-10-30
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-17